Asia Pacific Allergy最新文献

{"title":"Stapokibart (CM310) in patients with uncontrolled seasonal allergic rhinitis (PHECDA): Rationale and design of a multicentre, randomized, double-blind, placebo-controlled study.","authors":"Menglin Wang, Yuan Zhang, Jingyun Li, Chengshuo Wang, Luo Zhang","doi":"10.5415/apallergy.0000000000000174","DOIUrl":"10.5415/apallergy.0000000000000174","url":null,"abstract":"<p><strong>Background: </strong>Seasonal allergic rhinitis (SAR) is a global health issue, and the current standard of care (SoC) has limited effectiveness in controlling the disease. There is a need for innovative treatments to better manage uncontrolled SAR and advance beyond the uniform SoC, and biologics targeting type 2 inflammation driving allergic rhinitis is promising.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of Stapokibart, a humanized monoclonal antibody targeting interleukin-4 receptor subunit alpha, as an add-on therapy in patients with uncontrolled SAR.</p><p><strong>Methods: </strong>The PHECDA is a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study designed to evaluate the efficacy and safety of Stapokibart in treating uncontrolled SAR in adults. Conducted across 18 centers in China during the pollen season, the study plans to recruit 108 adult patients with moderate to severe nasal symptoms despite receiving SoC during the previous seasonal pollen period, along with a 1-week run-in period and a baseline blood eosinophil count of at least 300 cells·μL^-1. The study consists of a screening/run-in period (1 week), treatment period (4 weeks), and follow-up period (8 weeks). In addition to SoC, which includes mometasone furoate nasal spray and loratadine, participants are randomly assigned using a centralized interactive-web-response-system to receive either subcutaneous Stapokibart 600 (loading dose)-300 mg or a placebo every 2 weeks for 4 weeks. The primary endpoint of the study is the mean change from baseline in the daily reflective total nasal symptom score over the first 2 weeks of treatment. Subjects who have been administered at least 1 dose of the investigational drug will be included in the assessments of both efficacy and safety.</p><p><strong>Results: </strong>This article outlines the methodology utilized in a multicenter trial studying Stapokibar for seasonal allergic rhinitis, with expectations to discuss its significant effects in subsequent analyses based on trial outcomes.</p><p><strong>Conclusion: </strong>The PHECDA study is for the first time to provide insight into the efficacy and safety of a seasonal add-on Stapokibart for patients with uncontrolled SAR during pollen exposure.</p><p><strong>Trial registration: </strong>NCT05908032.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"15-20"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review for improper application of nasal spray in allergic rhinitis: A proposed role of community pharmacist for patient education and counseling in practical setting.","authors":"Anmar Al-Taie","doi":"10.5415/apallergy.0000000000000173","DOIUrl":"10.5415/apallergy.0000000000000173","url":null,"abstract":"<p><p>The application of nasal spray is encountered with technique errors, which can lead to decreased therapeutic response and treatment failure. Community pharmacists can play a pivotal role in providing appropriate knowledge and counseling services for the proper and effective use of these topical drugs. The aim of this systematic review was to assess the most important aspects of application technique errors and the impact of community pharmacist-led interventions on the provision of patient education and counseling regarding the application of these topical preparations in clinical practice. Preferred reporting items for systematic review and meta-analysis (PRISMA) criteria were used to set up a systematic search through different databases, including Scopus, Web of Science, and PubMed. A total of 10 articles were included in this study. Nearly three-quarters of the publications discussed improper technique, poor knowledge about installation technique, and poor adherence. Only 2 studies discussed pharmacist intervention, which comprised individualized brief education and training on the correct use of the nasal spray. The study highlights that there are many different aspects of application errors encountered by patients while using nasal spray. The study also highlights that there is a dearth of involvement of community pharmacists and pharmacist-led interventions for proper technique and application of these topical preparations.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"29-35"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882221/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective analysis of factors influencing response to omalizumab treatment in Indian patients with antihistamine refractory chronic spontaneous urticaria.","authors":"Thammannagowda Prarthana, Hitaishi Mehta, Anuradha Bishnoi, Davinder Parsad, Muthu Sendhil Kumaran","doi":"10.5415/apallergy.0000000000000184","DOIUrl":"10.5415/apallergy.0000000000000184","url":null,"abstract":"<p><strong>Background: </strong>Chronic spontaneous urticaria (CSU) presents as a persistent and distressing condition, with varying treatment responses. Omalizumab, a monoclonal anti-IgE antibody, has shown efficacy in managing antihistamine (AH₁)-refractory CSU, but its varied response patterns and associated factors remain understudied, particularly in India.</p><p><strong>Methods: </strong>We conducted a retrospective study involving 81 antihistamine-resistant CSU patients treated with omalizumab at a tertiary care center in Northern India between 2018 and 2023. Baseline characteristics, treatment response, and adverse effects were analyzed. Patients were categorized into various response groups based on treatment timelines and biomarker correlations.</p><p><strong>Results: </strong>We observed 65% achieved symptom cessation (group 1) following a single omalizumab dose, while 21% responded between second and third doses (group 2). A subset (7.4%) necessitated increased dosing frequency (group 3) for symptom control. Additionally, 6.2% showed persistent symptoms despite increased dosing frequency (group 4), exhibiting distinctive biomarker profiles indicative of an autoimmune endotype. Notably, 27.1% experienced exacerbations during treatment, emphasizing the need for tailored management approaches and response expectations.</p><p><strong>Conclusion: </strong>Omalizumab demonstrated remarkable efficacy in the treatment of AH₁-refractory CSU, with a good safety profile. This study highlights the complexity of treatment response to omalizumab and the potential utility of biomarkers in guiding personalized therapeutic strategies. Further research into biomarker-based endotypes is warranted to optimize CSU management.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"21-28"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retracted: Dermatological dichotomy: Atopic dermatitis or mycosis fungoides?","authors":"","doi":"10.5415/apallergy.0000000000000176","DOIUrl":"10.5415/apallergy.0000000000000176","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"43"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of azelastine hydrochloride and fluticasone propionate nasal spray in treating allergic rhinitis: A randomized controlled trial.","authors":"Xinling Han, Chengshuo Wang, Qinna Zhang, Bing Guan, Hua Zhang, Yafeng Yu, Jinyong Tang, Xiaoping Gao, Juan Meng, Chao Li, Huifang Zhou, Xinsheng Huang, Haiyun Shi, Tao Bian, Guohua Hu, Qingshan Jiang, Huabin Li, Lingbo Li, Xianhua Li, Chang Lin, Dingrong Liu, Jixiang Liu, Huaan Ma, Guolin Tan, Lijia Wan, Jiao Xia, Shuifang Xiao, Jinghua Xie, Zhimin Xing, Shenhong Qu, Changqing Zhao, Li Zhu, Yuan Zhang, Luo Zhang","doi":"10.5415/apallergy.0000000000000161","DOIUrl":"10.5415/apallergy.0000000000000161","url":null,"abstract":"<p><strong>Background: </strong>MP-AzeFlu (Dymista; Meda Pharma GmbH & Co., KG), a formulation combining azelastine hydrochloride and fluticasone propionate in a single spray, is superior to fluticasone propionate alone in relieving symptoms and improving the quality of life of patients with allergic rhinitis.</p><p><strong>Objectives: </strong>In this study, we evaluated whether the effect of AzeFlu, a generic drug manufactured from China, is equivalent to that of MP-AzeFlu.</p><p><strong>Methods: </strong>In total, 679 patients were recruited for a multicentre, randomized, double-blind, original drug-controlled, and parallel-group clinical trial. Overall, 339 and 340 patients were administered with AzeFlu and MP-AzeFlu, respectively. Efficacy was assessed by changes in the reflective total nasal symptom score, the area under the curve of reflective total nasal symptom score changes over time, changes from baseline in individual nasal symptom scores, and the Rhinoconjunctivitis Quality of Life Questionnaire. In addition, a safety evaluation was simultaneously performed.</p><p><strong>Results: </strong>AzeFlu and MP-AzeFlu reduced the reflective total nasal symptom score from baseline (AzeFlu -6.7 [standard deviation, 2.59]; MP-AzeFlu -6.7 [standard deviation, 2.76]; <i>P</i> = 0.905) and improved nasal symptoms and quality of life (AzeFlu -62.3 [standard deviation, 33.59]; MP-AzeFlu -64.7 [standard deviation, 33.73]; <i>P</i> = 0.394) in patients with allergic rhinitis. Significant differences were not observed between groups.</p><p><strong>Conclusion: </strong>AzeFlu showed effects equivalent to those of MP-AzeFlu in this clinical trial and may benefit Chinese patients with allergic rhinitis.<b>Registration number:</b> CTR20190189 (chinadrugtrials.org.cn/index.html).</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"7-14"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Banana-dependent exercise-induced anaphylaxis.","authors":"Öner Özdemir","doi":"10.5415/apallergy.0000000000000168","DOIUrl":"10.5415/apallergy.0000000000000168","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"42"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effective desensitization in an IgE-mediated hypersensitivity reaction to tocilizumab in neuromyelitis optica.","authors":"Francisca Cunha, Pedro Alves, João Cardoso Lopes, Carmelita Ribeiro, Ana Todo Bom","doi":"10.5415/apallergy.0000000000000170","DOIUrl":"10.5415/apallergy.0000000000000170","url":null,"abstract":"<p><p>Neuromyelitis optica is a rare, inflammatory autoimmune disease of the central nervous system. Tocilizumab is a humanized monoclonal antibody, which targets the inhibition of the interleukin-6 receptor, a mediator with an important role in the pathophysiological mechanism of neuromyelitis optica. Hypersensitivity reactions to tocilizumab are rare, but similar to other biological drugs can elicit a hypersensitivity reaction. The authors present a case of a 50-year-old female patient, with a neuromyelitis optica, with a severe reaction at the 6th cycle of treatment. The patient was referred to Drug Allergy Consultation, where she underwent tocilizumab skin tests: intradermal test 1/1,000 with a positive result. The patient was then proposed for drug desensitization, and, to date, the patient has undergone 22 desensitization cycles, all of which were uneventful. This case emphasizes the importance of trying to phenotype the hypersensitivity reactions to monoclonal antibodies, and therefore invest in an allergy workup to make the best decision for our patients.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"39-41"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in patients with hereditary angioedema correlates with angioedema control: Our experience at Chandigarh, India.","authors":"Rajni Sharma, Suprit Basu, Reva Tyagi, Sangeetha Siniah, Prabal Barman, Archan Sil, Sanghamitra Machhua, Sanchi Chawla, Vignesh Pandiarajan, Rakesh Kumar Pilania, Saniya Sharma, Manpreet Dhaliwal, Deepti Suri, Amit Rawat, Sendhil M Kumaran, Sunil Dogra, Surjit Singh, Ankur Kumar Jindal","doi":"10.5415/apallergy.0000000000000172","DOIUrl":"10.5415/apallergy.0000000000000172","url":null,"abstract":"<p><strong>Background: </strong>Hereditary angioedema (HAE) is characterized by unpredictable acute attacks that impair the patient's quality of life (QoL) not only due to the impact on functional abilities caused by edema but also due to pain and other symptoms, including fatigue, nausea, and vomiting.</p><p><strong>Objectives: </strong>QoL studies in patients with HAE have not been carried out in the Indian subcontinent. Hence, we carried out this study to assess the QoL and to identify factors associated with impaired QoL in patients with HAE.</p><p><strong>Methods: </strong>This was a cross-sectional observational study carried out in confirmed cases of HAE, aged >18 years, using angioedema QoL score and angioedema control test.</p><p><strong>Results: </strong>We enrolled 135 patients with HAE (aged 18-80 years) with a mean age of 40.93 years. We observed that the QoL directly correlates with angioedema control and is also affected by other factors such as gender, duration of follow-up, and the frequency of episodes. Genitalia swelling, positive family history, and presence of mortality due to HAE in the family also significantly impact the QoL of patients with HAE. In addition, patients with type 1 HAE reported a poorer QoL as compared to patients with type 2 HAE.</p><p><strong>Conclusion: </strong>We report the QoL of patients with HAE from settings where none of the first-line medications are available. Results of the study suggest that disease control is the most important factor that influences the QoL.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 1","pages":"1-6"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-utility and clinical outcome analysis of surgery or oral corticosteroids treatment in patients with chronic rhinosinusitis with nasal polyps.","authors":"Jing Zhang, Yutong Sima, Shan Shao, Ming Zheng, Yan Zhao, Fei Gao, Xiangdong Wang, Luo Zhang","doi":"10.5415/apallergy.0000000000000160","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000160","url":null,"abstract":"<p><strong>Background: </strong>Surgery and oral corticosteroids are recommended therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) patients who are nonresponsive to intranasal corticosteroid treatment.</p><p><strong>Objective: </strong>This study aimed to compare the effectiveness of these 2 treatments in terms of improving sinus-related symptoms, enhancing quality of life, and economic costs and duration costs.</p><p><strong>Methods: </strong>This prospective study enrolled CRSwNP patients. All participants were instructed to complete the 22-item Sino-Nasal Outcome Test (SNOT-22), visual analog scale, and 36-item short-form (SF-36) questionnaire at baseline and 3 months after treatment. The nasal polyp score (NPS) was assessed via endoscopic examination. Additionally, patients were requested to maintain records of economic direct costs, other indirect costs, and duration costs throughout the 3-month period and to report them during each follow-up visit.</p><p><strong>Results: </strong>A total of 40 patients who underwent surgery or received oral corticosteroids were enrolled in this study. After 3 months of treatment, significant improvements were observed between baseline and 3 months after treatment in the NPS, total SNOT-22 score, and nasal congestion, runny nose, facial pain, olfactory function, and overall symptoms measured. Only headache and sleep order were improved in the surgery group. Both physical functioning and general health, as measured by the SF-36, improved after both treatments, and the role-physical, bodily pain, and social functioning domains of the SF-36 improved only in the surgery group. The changes in the NPS, nasal congestion, runny nose, olfactory function, and sleep disorders in the surgery group were greater than those in the oral corticosteroid group (<i>P</i> values = 0.0003, 0.0092, 0.0258, 0.0284, and 0.0164, respectively). Changes in the total SNOT-22 score and SF-36 subscores were not different between the 2 treatment groups. The direct economic costs and duration costs of surgical treatment were 4.5 times and 17.0 times higher, respectively, than those of oral corticosteroid treatment.</p><p><strong>Conclusions: </strong>Both surgical and oral corticosteroid treatments effectively improved clinical symptoms and quality of life in patients with CRSwNP. Patients who underwent surgery exhibited greater improvements in sinus-related symptoms. Nevertheless, oral corticosteroid treatment presented notable advantages in terms of economic cost and duration cost of disease-related care.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 4","pages":"174-182"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of autophagy-related genes and exploration of their relationship with disease severity in chronic rhinosinusitis with nasal polyps.","authors":"Jiajia Zi, Longgang Yu, Lin Wang, Xudong Yan, Danyang Li, Xiaoyun Du, Jisheng Zhang, Yan Jiang","doi":"10.5415/apallergy.0000000000000159","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000159","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) pathogenesis might be impacted by autophagy. Nevertheless, autophagy-related gene utilization as a disease indicator about the course of CRSwNP has yet to be elucidated.</p><p><strong>Objective: </strong>This investigation aimed at discovering pivotal molecules related to autophagy to identify potential treatment targets for CRSwNP.</p><p><strong>Methods: </strong>The dataset GSE136825 was obtained via the Gene Expression Omnibus (GEO) database, and afterward, differentially expressed genes (DEGs) analysis linked to autophagy was employed via the R software. A comprehensive examination of autophagy-related DEGs was conducted using functional analytic techniques. The utilization of the protein-protein interaction (PPI) network facilitated hub gene identification. Quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry staining techniques were performed to validate the expression levels of the central genes in clinical samples. Correlation analysis was performed to examine the correlation between hub genes and disease severity parameters.</p><p><strong>Results: </strong>A comprehensive set of 86 autophagy-related DEGs were discovered. The functional enrichment analysis of autophagy-related DEGs revealed the identification of enrichment terms involved with the autophagy process. The results obtained from the PPI analysis suggest that there was interaction among the autophagy-related genes. The qRT-PCR, immunohistochemistry staining, and western blot techniques yielded results, demonstrated that <i>CXCR4</i>, <i>HMOX1</i>, and <i>SPP1</i> expression levels in CRSwNP agreed with the bioinformatics analysis of the dataset. Furthermore, a favorable association between <i>CXCR4</i>, <i>HMOX1</i>, and <i>SPP1</i> expression levels with illness severity indicators was found.</p><p><strong>Conclusion: </strong>Bioinformatics analysis yielded 86 autophagy-related DEGs in CRSwNP. <i>CXCR4</i>, <i>HMOX1</i>, and <i>SPP1</i> regulation of autophagy has been confirmed in CRSwNP progression and pathogenesis.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 4","pages":"162-173"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}